Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Apatinib for Stage III NSCLC with Radiation Pneumonitis
NCT06700421Phase 2Active, not recruiting
- Start
- Aug 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of adebrelimab and Rivoceranib in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Progression-Free Survival at 12 months. Started Aug 2024; status: active, not recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06700421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06700421.